Amplification of the mdr1-gene is uncommon in recurrent ovarian carcinomas.
- 1 November 1999
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 146 (2) , 195-199
- https://doi.org/10.1016/s0304-3835(99)00263-3
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancerAnti-Cancer Drugs, 1998
- Modulation and prevention of multidrug resistance by inhibitors of P-glycoproteinCancer Chemotherapy and Pharmacology, 1997
- Search for specific inhibitors of multidrug resistance in cancerSeminars in Cancer Biology, 1997
- Co-expression of MDR-associated markers, including P-170, MRP and LRP and cytoskeletal proteins, in three resistant variants of the human ovarian carcinoma cell line, OAW42European Journal Of Cancer, 1997
- MDR1 gene expression in solid tumoursEuropean Journal Of Cancer, 1996
- MDR1 and multidrug resistance-associated protein (MRP) gene expression in epithelial ovarian tumorsCancer Letters, 1996
- P-Glycoproteins and Multidrug ResistanceAnnual Review of Pharmacology and Toxicology, 1996
- GENETIC ANALYSIS OF THE MULTIDRUG TRANSPORTERAnnual Review of Genetics, 1995
- P-glycoprotein, multidrug resistance and tumor progressionCancer and Metastasis Reviews, 1994
- BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTERAnnual Review of Biochemistry, 1993